Celldex Therapeutics, Inc. (CLDX) - Stock Analysis
Last updated: Mar 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Completion of enrollment in two global Phase 3 EMBARQ-CSU trials and multiple Phase 2 data presentations at AAAAI (Feb 27âMar 2) have ignited a ~35% short-term rally; near-term scientific disclosures can drive further spikes, making CLDX a tactically attractive, event-driven biotech trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Very strong liquidity ⢠Deep cash burn ⢠Minimal revenue CLDX has a very strong balance sheet and low leverage but is burning cash with deeply negative profitability and negligible revenue, leaving its ~ $2.05B market valuation disconnected from fundamentals.
Price Behavior
Key Price Behavior Insights: ⢠Short-term uptrend ⢠Gap-driven support ⢠Concentrated spike Support Level: $24.30 Resistance Level: $30â$31 Over the last month CLDX rallied from $23.57 to $29.51, led by a lateâFeb gap that set support near $24.30 and resistance at $30â$31, but the concentrated ~25% spike and rising volatility increase meanâreversion risk if price falls into the low $20s.
Sentiment & News
Key News Insights: ⢠Phase 3 enrollment ⢠Sustained off-treatment efficacy ⢠QoL improvement Celldex completed global Phase 3 enrollment for barzolvolimab after Phase 2 AAAAI data showed sustained off-treatment efficacy, tryptase normalization and meaningful quality-of-life gains, advancing a potential first-in-class therapy toward late-stage readouts.
AI Summary
Celldex has shifted from an earlyâstage developer to a nearâterm, binary commercialization bet driven almost entirely by the probability of positive Phase 3 barzolvolimab readouts and potential diseaseâmodifying label claims; monitor the Phase 3 results and whether management secures nonâdilutive/partner funding because the company's cash runway (excluding illiquid investments) and current valuation are fragile to a negative outcome.
Description
Celldex Therapeutics is a biopharmaceutical company developing monoclonal and bispecific antibody therapies for inflammatory conditions and various cancers. Its clinical pipeline includes programs directed at KIT, CD40 and a bispecific combining PD-L1 blockade with CD27 costimulation, among other antibody candidates. The company maintains research and licensing relationships with academic institutions and Amgen, and is headquartered in Hampton, New Jersey, having been incorporated in 1983.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 26 | Mar 5 | CLDX | Celldex Therapeutics, Inc. | Completion of enrollment in two global Phase 3 EMBARQ-CSU trials and multiple Phase 2 data presentations at AAAAI (Feb 27âMar 2) have ignited a ~35% short-term rally; near-term scientific disclosures can drive further spikes, making CLDX a tactically attractive, event-driven biotech trade. | Closed | -4.2% |